Clinical Trial Update: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) [Phase 2]

View source ↗

Summary

A Phase 2 placebo-controlled trial evaluating the safety, tolerability, and efficacy of RO7017773 in individuals with Autism Spectrum Disorder aged 15-45 years …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• RO7017773 (RO7017773)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Autism Spectrum Disorder (ASD) | Phase 2 | Status: COMPLETED | Results posted: 2025-01-28